In prostate cancer, FoundationOne Liquid CDx is indicated for use as a companion diagnostic for four FDA-approved precision therapies, including an indication for Rubraca (rucaparib), a PARP inhibitor approved for the treatment of metastatic castration-resistant prostate cancer patients with BRCA1/2 mutations. Here, BRCA1 is linked to prostate cancer.